Get the Stockscreener App
1.90
0.52%
-0.01
After Hours:
1.88
-0.02
-1.05%
Hookipa Pharma Inc stock is traded at $1.90, with a volume of 35,861.
It is down -0.52% in the last 24 hours and up +3.26% over the past month.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
See More
Previous Close:
$1.91
Open:
$1.9
24h Volume:
35,861
Relative Volume:
0.29
Market Cap:
$22.90M
Revenue:
$52.16M
Net Income/Loss:
$-48.60M
P/E Ratio:
-0.4398
EPS:
-4.32
Net Cash Flow:
$-77.48M
1W Performance:
-5.00%
1M Performance:
+3.26%
6M Performance:
-62.89%
1Y Performance:
-71.64%
1-Day Range:
$1.89
$1.9641
1-Week Range:
$1.835
$2.08
52-Week Range:
$1.715
$10.50
Hookipa Pharma Inc Stock (HOOK) Company Profile
Name
Hookipa Pharma Inc
Sector
Industry
Phone
0114318906360
Address
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
Compare HOOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
1.90 | 22.90M | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-15-24 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-08-21 | Initiated | Morgan Stanley | Overweight |
| Nov-03-20 | Initiated | Truist | Buy |
| Oct-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-19-20 | Resumed | H.C. Wainwright | Buy |
| Sep-27-19 | Initiated | H.C. Wainwright | Buy |
| May-13-19 | Initiated | BofA/Merrill | Buy |
| May-13-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Hookipa Pharma Inc Stock (HOOK) Latest News
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial - Yahoo Finance
Hookipa Pharma Files Petition to Validate Stockholder Actions at Annual Meetings - Defense World
HOOKIPA completes enrollment for HIV vaccine trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma seeks court validation for stockholder actions By Investing.com - Investing.com Australia
HOOKIPA completes enrollment for HIV vaccine trial - Investing.com India
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire
Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - StockTitan
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment… - Informazione.it
Poolbeg Agrees to Bid Deadline Extension for Possible Hookipa Pharma Deal - MarketWatch
Poolbeg and HOOKIPA given more time to agree merger deal - Proactive Investors USA
Poolbeg Pharma PLC (AIM:POLB) Offer Update – Extension to PUSU Deadline - Share Talk
Poolbeg Pharma granted extension to PUSU Deadline - DirectorsTalk Interviews
Poolbeg Pharma and HOOKIPA Extend Merger Deadline Amid Positive Discussions - TipRanks
HOOKIPA Pharma seeks court validation for stockholder actions - MSN
Hookipa Pharma Seeks Validation for Stockholder Meetings - TipRanks
HOOK (HOOKIPA Pharma) Shares Outstanding (EOP) : 12.05 Mil (As of Sep. 2024) - GuruFocus.com
Hookipa Pharma stock hits 52-week low at $1.73 amid market challenges - Investing.com Nigeria
Geode Capital Management LLC Cuts Stake in Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
HC Wainwright Reiterates Neutral Rating for Hookipa Pharma (NASDAQ:HOOK) - Defense World
HOOKIPA Pharma explores acquisition of Poolbeg Pharma By Investing.com - Investing.com South Africa
HOOKIPA Pharma explores acquisition of Poolbeg Pharma - Investing.com
Poolbeg Pharma notes Gilead interest in Hookipa fundraise -January 10, 2025 at 11:08 am EST - Marketscreener.com
Poolbeg Pharma PLC (AIM:POLB) Update Potential Combination of Poolbeg & HOOKIPA - Share Talk
Poolbeg Pharma update on potential combination with HOOKIPA - DirectorsTalk Interviews
Poolbeg Pharma plc ('Poolbeg”) and HOOKIPA Pharma Inc. ('HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - The Manila Times
Poolbeg Pharma and HOOKIPA Explore Potential Merger Amid Gilead’s Interest - TipRanks
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. - GlobeNewswire
Gilead Sciences Backs HOOKIPA-Poolbeg Merger Talks with $8.7M Funding Commitment - StockTitan
HOOKIPA Pharma discloses position in takeover code filing By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Inc. Enters Non-Binding Discussions for Potential Acquisition of Poolbeg Pharma plc - Defense World
HOOKIPA Pharma discloses position in takeover code filing - Investing.com India
UPDATEMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
HOOKIPA Pharma IncFORM 8 (OPD) - GlobeNewswire
HOOKIPA Pharma Discloses Executive Stock Holdings, Awards Major RSU Grants to Leadership - StockTitan
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements - The Manila Times
HOOKIPA Pharma Issues Key Disclosure Notice for Poolbeg Pharma Acquisition Plans - StockTitan
Poolbeg and HOOKIPA progress toward potential merger By Investing.com - Investing.com Australia
HOOKIPA Pharma in talks to acquire Poolbeg Pharma By Investing.com - Investing.com Australia
HOOKIPA Pharma in talks to acquire Poolbeg Pharma - Investing.com
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
Poolbeg and HOOKIPA progress toward potential merger - Investing.com India
Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA - Proactive Investors Australia
Hookipa Pharma Inc Stock (HOOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):